Phase 1b Study of the Efficacy and Safety of CAR2 Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases Resistant to Standard Therapy Using the HITM Method and Pressure Enabled Delivery Device
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Anti CEA CAR T cell therapy Sorrento Therapeutics (Primary)
- Indications Adenocarcinoma; Liver metastases; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms AntiCEA_CART
- Sponsors Sorrento Therapeutics
Most Recent Events
- 28 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 18 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2019 New trial record